Press Release
ONCOLYS BIOPHARMA INC.
(TSE Mothers: 4588)
19 October 2017

TelomeScan® Clinical Study conducted by Okayama University to be Presented at the 55th Annual Meeting of JSCO

Tokyo, JAPAN: The data of a clinical study using Oncolys Biopharma’s oncolytic virus TelomeScan® (OBP-401) for the detection of tumor cells from digestive organ cancer patients’ blood and peritoneal washing, conducted by a group of experts led by Dr. Toshiyoshi Fujiwara, Okayama University, will be presented on Friday 20th October 2017 at Symposium 1 in the 55th Annual Meeting of Japan Society of Clinical Oncology (“JSCO”) in Yokohama, Japan.

Details of the presentation are as below:

【Symposium 1 - The 55th Annual Meeting of JSCO】
Time & Date: Fri 20 October 2017, 08:40 – 11:10 (Symposium 1)
Venue: Room 1 | Conference Center 1F Main Hall, PACIFICO Yokohama
Theme: "Clinical application of tumor cell detection system using a tumor-specific fluorescence virus TelomeScan"
Speaker: Hiroshi Tazawa MD, PhD, Okayama University Hospital

For more information, please visit the JSCO website: http://congress.jsco.or.jp/jsco2017/english/

# # #

About Oncolys BioPharma Inc.: Oncolys BioPharma is a TSE Mothers-listed biopharmaceutical company with focuses on the development of novel biologics for the treatment of cancer and infectious diseases. The company’s lead product for the treatment of cancer, Telomelysin® (OBP-301), is based on replication-competent oncolytic virus, and is being tested in Phase I/II clinical trial in Asia and Phase II in the USA, for various solid tumors. A novel cancer diagnostic product, TelomeScan® (OBP-401/1101), is expected to be effective in detecting various types of cancer and inflammatory diseases and adopted in several private practices. The company also has a major program OBP-601 (Censavudine) for infectious diseases, for which it completed Phase II clinical trial in the U.S. for HIV/AIDS therapy, supported by BMS. For more information, please visit http://www.oncolys.com/en/

Oncolys BioPharma Inc.
Mie Yamazaki
Investors Relations & Corporate Communications
Tel: +81 (0) 5472 1578
Email: yamazaki@oncolys.com